Do Not Hold Aspirin Before Most Biopsies
For the vast majority of biopsies, aspirin should NOT be discontinued and can be continued throughout the procedure. The only exception requiring aspirin cessation is for high-risk procedures with significant bleeding potential, where aspirin should be stopped 5 days before the procedure 1.
Risk-Stratified Approach
Low-Risk Procedures (Continue Aspirin)
Diagnostic procedures with biopsy are classified as LOW-RISK procedures 1. For these procedures:
- Continue aspirin without interruption (strong recommendation)
- This includes most routine biopsies:
- Endoscopic biopsies (esophageal, gastric, duodenal, colonic)
- EUS without interventional therapy
- Most percutaneous biopsies
The rationale is clear: the thrombotic risk from stopping aspirin outweighs the minimal bleeding risk from continuing it during standard biopsy procedures 1.
High-Risk Procedures (Stop Aspirin 5 Days Before)
Only specific high-bleeding-risk procedures require aspirin discontinuation:
- Neurosurgery and intracranial biopsies 2
- Ampullectomy (weak recommendation) 1
- Large polypectomy (>2cm)
- Endoscopic submucosal dissection (ESD)
- Endoscopic mucosal resection (EMR)
For these procedures: Stop aspirin 5 days (not 7-10 days) before the procedure 2, 3. This 5-day window allows sufficient platelet function recovery while minimizing thrombotic risk from prolonged cessation.
Supporting Evidence
Recent high-quality research confirms aspirin safety during biopsies:
- Kidney biopsies: A 2023 study of 750 patients showed no increased major complications in patients receiving aspirin within 5 days of percutaneous kidney biopsy (2.59% vs 3.19%, p=0.74) 4
- Liver biopsies: Pediatric transplant liver biopsies showed no difference in adverse events with aspirin continuation 5
- Platelet recovery: Aspirin's antiplatelet effect normalizes within 96-144 hours (4-6 days), supporting the 5-day discontinuation window when needed 3
Critical Pitfalls to Avoid
Do not routinely stop aspirin 7-10 days before procedures - This outdated practice increases thrombotic risk unnecessarily. The evidence supports 5 days maximum when discontinuation is truly needed 2, 3
Always counsel patients about thrombotic risks - Patients must understand that stopping aspirin carries stroke/MI risk, particularly in those on aspirin for secondary prevention 1
Distinguish aspirin from P2Y12 inhibitors - Clopidogrel, prasugrel, and ticagrelor require 7-day discontinuation for high-risk procedures, but aspirin should be continued even when these are stopped 1
Resume aspirin quickly post-procedure - Restart within 1-2 days after the procedure to minimize thrombotic window 1
Practical Algorithm
Step 1: Classify the biopsy procedure
- Low-risk (most biopsies) → Continue aspirin
- High-risk (neurosurgery, ampullectomy, large resections) → Proceed to Step 2
Step 2: For high-risk procedures only
- Stop aspirin 5 days before procedure
- Continue aspirin if patient is on dual antiplatelet therapy (DAPT) - only stop the P2Y12 inhibitor
- Consult cardiology if patient has recent coronary stent (<12 months drug-eluting, <1 month bare metal)
Step 3: Resume aspirin 1-2 days post-procedure based on hemostasis
This evidence-based approach prioritizes patient safety by balancing bleeding risk against the more consequential thrombotic complications that can result from unnecessary aspirin discontinuation.